(19)

(11)

EP 4 114 360 A1

(12)

(43) Date of publication: 11.01.2023 Bulletin 2023/02 (21) Application number: 21764886.4 (22) Date of filing: 04.03.2021

(51) International Patent Classification (IPC):  A61K 9/10(2006.01) B82Y 5/00(2011.01) A61K 9/127(2006.01) (52) Cooperative Patent Classification (CPC): A61P 9/10; C12N 2310/20; C12N 2310/315; C12N 2310/346; C12N 15/113; C12N 15/111; A61K 47/549; A61K 47/6929; C12N 15/87; C12N 2750/14143; C12N 2710/10343; C12N 15/88   C-Sets: C12N 2310/321, C12N 2310/3521; (86) International application number: PCT/US2021/020955 (87) International publication number: WO 2021/178725 (10.09.2021 Gazette 2021/36)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA ME Designated Validation States: KH MA MD TN (30) Priority: 04.03.2020 US 202062984866 P 16.09.2020 US 202063078982 P (71) Applicant: Verve Therapeutics, Inc. Cambridge, MA 02139 (US)	(72) Inventors: RAJEEV, Kallanthottathil, G. Cambridge, MA 02139 (US) BISWAS, Souvik Cambridge, MA 02139 (US) MALYALA, Padma Cambridge, MA 02139 (US) KASIEWICZ, Lisa, N. Cambridge, MA 02139 (US) CHADWICK, Alexandra Cambridge, MA 02139 (US) REISS, Caroline Cambridge, MA 02139 (US) (74) Representative: HGF  HGF Limited 1 City Walk Leeds LS11 9DX Leeds LS11 9DX (GB)